Literature DB >> 26884288

Complete recovery of visual acuity as the main goal of treatment in patients with dysthyroid optic neuropathy.

Piotr Miśkiewicz1, Beata Rutkowska, Anna Jabłońska, Antoni Krzeski, Katarzyna Trautsolt-Jeziorska, Dariusz Kęcik, Justyna Milczarek-Banach, Katarzyna Pirko-Kotela, Agnieszka Samsel, Tomasz Bednarczuk.   

Abstract

INTRODUCTION: To evaluate the effectiveness of methylprednisolone (MP) and surgical treatment in achieving complete reversal of dysthyroid optic neuropathy (DON) and predictive factors of this therapy.
MATERIAL AND METHODS: The group consisted of 10 patients (18 eyes) with DON. The diagnosis of DON was based on at least two criteria from the following: (i) deterioration of visual acuity (VA< 1.0), (ii) loss of colour vision, (iii) optic disc swelling, and/or (iv) signs of DON in magnetic resonance imaging (presence of apical crowding and/or optic nerve stretching). A complete recovery of DON was defined as the normalisation of VA (VA = 1.0), normal colour vision, and reversal of optic disc swelling. A significant improvement was defined as improvement of VA of at least 0.2. The consecutive steps of treatment of DON consisted of: (i) first-line treatment - intravenous MP pulse therapy (3 × 1 g); (ii) second-line treatment - endoscopic intranasal orbital decompression of medial wall; (iii) additional treatment - additional MP therapy and/or surgical decompression.
RESULTS: A significant improvement in VA could be achieved in the majority of patients; a complete recovery was noted in 22.2%, 33.3%, and 66.7% of eyes after first-line, second-line, and additional treatment, respectively. Positive predictive factors were: younger age (p = 0.049), shorter duration of DON (p = 0.035), and a higher Graves' orbitopathy clinical activity score (p = 0.035).
CONCLUSIONS: By using combination therapy (intravenous MP pulse therapy and surgical decompression), a complete recovery can be achieved in the majority of patients with DON.

Entities:  

Keywords:  Graves’ disease; Graves’ orbitopathy; dysthyroid optic neuropathy; endoscopic intranasal orbital decompression; methylprednisolone; orbital decompression

Mesh:

Substances:

Year:  2016        PMID: 26884288     DOI: 10.5603/EP.a2016.0018

Source DB:  PubMed          Journal:  Endokrynol Pol        ISSN: 0423-104X            Impact factor:   1.582


  13 in total

1.  Retinal nerve fiber layer thickness measured by optical coherence tomography predicts visual recovery after orbital decompression for dysthyroid optic neuropathy.

Authors:  Xinghua Wang; Fagang Jiang; Shengnan Cheng; Yueqi Yu; Yayan You; Jin Chen; Xiaohuan Pi
Journal:  Int Ophthalmol       Date:  2021-05-04       Impact factor: 2.031

Review 2.  Orbital decompression for thyroid eye disease: methods, outcomes, and complications.

Authors:  J M Jefferis; R K Jones; Z I Currie; J H Tan; S M Salvi
Journal:  Eye (Lond)       Date:  2017-12-15       Impact factor: 3.775

3.  A Case of Compressive Optic Neuropathy Secondary to Lymphoma of the Extraocular Muscles.

Authors:  Yoshiyuki Kitaguchi; Atsushi Watanabe; Kohji Nishida
Journal:  Neuroophthalmology       Date:  2019-05-02

4.  Prevalence of Radiological Signs of Dysthyroid Optic Neuropathy in Magnetic Resonance Imaging in Patients with Active, Moderate-to-Severe, and Very Severe Graves Orbitopathy.

Authors:  Beata Rutkowska-Hinc; Edyta Maj; Anna Jabłońska; Justyna Milczarek-Banach; Tomasz Bednarczuk; Piotr Miśkiewicz
Journal:  Eur Thyroid J       Date:  2018-02-15

5.  Influence of Methylprednisolone Pulse Therapy on Liver Function in Patients with Graves' Orbitopathy.

Authors:  Piotr Miśkiewicz; Anna Jankowska; Kinga Brodzińska; Justyna Milczarek-Banach; Urszula Ambroziak
Journal:  Int J Endocrinol       Date:  2018-10-21       Impact factor: 3.257

6.  Comparison of 2-wall versus 3-wall orbital decompression against dysthyroid optic neuropathy in visual function: A retrospective study in a Chinese population.

Authors:  Sheng-Nan Cheng; Yue-Qi Yu; Ya-Yan You; Jin Chen; Xiao-Huan Pi; Xing-Hua Wang; Fa-Gang Jiang
Journal:  Medicine (Baltimore)       Date:  2021-02-26       Impact factor: 1.817

7.  Dysthyroid optic neuropathy: update on pathogenesis, diagnosis, and management.

Authors:  Alexander D Blandford; Dalia Zhang; Rao V Chundury; Julian D Perry
Journal:  Expert Rev Ophthalmol       Date:  2017-01-27

Review 8.  Fat-removal orbital decompression for thyroid associated orbitopathy: The right procedure for the right patient.

Authors:  Eman Al-Sharif; Adel H Alsuhaibani
Journal:  Saudi J Ophthalmol       Date:  2017-06-14

9.  The Therapeutic Effect of Combination of Orbital Decompression Surgery and Methylprednisolone Pulse Therapy on Patients with Bilateral Dysthyroid Optic Neuropathy.

Authors:  Jianan Xu; Huijing Ye; Guo Chen; Jingqiao Chen; Rongxin Chen; Huasheng Yang
Journal:  J Ophthalmol       Date:  2020-02-19       Impact factor: 1.909

10.  Early efficacy of teprotumumab for the treatment of dysthyroid optic neuropathy: A multicenter study.

Authors:  Connie M Sears; Yao Wang; Lucy A Bailey; Roger Turbin; Prem S Subramanian; Raymond Douglas; Kimberly Cockerham; Andrea L Kossler
Journal:  Am J Ophthalmol Case Rep       Date:  2021-05-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.